Abstract:Objective Improved understanding of cyclosporine A (CsA) pharmacokinetics in children undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) is crucial for effective prevention of acute graft-versus- host disease and medication safety. The aim of this study was to establish a population pharmacokinetic (Pop-PK) model that could be used for individualised therapy to paediatric patients undergoing allo-HSCT in China. Design, setting and participants A retrospective analysis of 251 paediatric HSCT patients who received CsA intravenously in the early post transplantation period at Women and Children's Medical Center in Guangzhou was conducted. Analysis measures The model building dataset from 176 children was used to develop and analyse the CsA Pop-Pk model by using the nonlinear mixed effect model method. The basic information was collected by the electronic medical record system. Genotype was analysed by matrix-assisted time-of- flight mass spectrometry. The stability and predictability of the final model were verified internally, and a validation dataset of 75 children was used for external validation. Monte Carlo simulation is used to adjust and optimise the initial dose of CsA in paediatric allo-HSCT patients. Results The typical values for clearance (CL) and volume of distribution (Vd) were 14.47 L/hour and 2033.53 L, respectively. The body weight and haematocrit were identified as significant variables for V, while only body weight had an impact on CL. The simulation based on the final model suggests that paediatrics with HSCT required an appropriate intravenous dose of 5 mg/kg/day to reach the therapeutic trough concentration. Conclusions The CsA Pop-PK model established in this study can quantitatively describe the factors influencing pharmacokinetic parameters and precisely predict the intrinsic exposure to CsA in children. In addition, our dosage simulation results can provide evidence for the personalised medications

Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients

The Dosage Recommendation of Cyclosporin in Children with Hemophagocytic Lymphohistiocytosis Based on Population Pharmacokinetic Model

Age Difference of Cyclosporin Dosage in Pediatric Patients

Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Initial Dosage Optimisation of Cyclosporine in Chinese Paediatric Patients Undergoing Allogeneic Haematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics: a Retrospective Study.

Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients

Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients.

Population Pharmacokinetics of Cyclosporine in Chinese Children Receiving Hematopoietic Stem Cell Transplantation

Study on population pharmacokinetics of cyclosporine in children with aplastic anemia

Population Pharmacokinetics and Individualized Dosage Prediction of Cyclosporine in Allogeneic Hematopoietic Stem Cell Transplant Patients

Population Pharmacokinetics of Ciclosporin in Chinese Children with Aplastic Anemia: Effects of Weight, Renal Function and Stanozolol Administration

Population Pharmacokinetics Model and Initial Dose Optimization of Tacrolimus in Children and Adolescents with Lupus Nephritis Based on Real-World Data

Population Pharmacokinetic Study Of Cyclosporine In Hematopoietic Stem Cell Transplant Recipients

Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration

Influence of pediatric diseases on cyclosporine pharmacokinetics investigated by non-linear mixed effects model

Population Pharmacokinetics and Initial Dose Optimization of Tacrolimus in Children with Severe Combined Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics

Population Pharmacokinetics of Tacrolimus in Pediatric Patients with Systemic-Onset Juvenile Idiopathic Arthritis: Initial Dosage Recommendations

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Population Pharmacokinetics and Pharmacogenomics of Tacrolimus in Chinese Children Receiving a Liver Transplant: Initial Dose Recommendation